Souders Financial Advisors boosted its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 4.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,264 shares of the healthcare product maker’s stock after buying an additional 1,734 shares during the period. Souders Financial Advisors’ holdings in Abbott Laboratories were worth $4,496,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Abbott Laboratories by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 165,301,921 shares of the healthcare product maker’s stock valued at $18,788,216,000 after buying an additional 8,834,840 shares in the last quarter. Capital Research Global Investors boosted its holdings in Abbott Laboratories by 9.5% in the 4th quarter. Capital Research Global Investors now owns 86,588,614 shares of the healthcare product maker’s stock worth $9,530,825,000 after buying an additional 7,527,778 shares during the last quarter. Capital International Investors boosted its holdings in Abbott Laboratories by 9.1% in the 1st quarter. Capital International Investors now owns 70,177,564 shares of the healthcare product maker’s stock worth $7,976,382,000 after buying an additional 5,882,780 shares during the last quarter. Swedbank AB acquired a new stake in Abbott Laboratories in the 1st quarter worth about $341,777,000. Finally, Sessa Capital IM L.P. acquired a new stake in Abbott Laboratories in the 2nd quarter worth about $264,876,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Insider Activity
In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the completion of the transaction, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.10% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on ABT
Abbott Laboratories Stock Up 1.4 %
Shares of ABT opened at $114.01 on Tuesday. The firm has a market cap of $198.34 billion, a PE ratio of 35.52, a price-to-earnings-growth ratio of 2.86 and a beta of 0.72. The company’s fifty day moving average is $111.78 and its two-hundred day moving average is $108.16. Abbott Laboratories has a fifty-two week low of $89.67 and a fifty-two week high of $121.64. The company has a quick ratio of 1.18, a current ratio of 1.68 and a debt-to-equity ratio of 0.33.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The business had revenue of $10.38 billion for the quarter, compared to the consensus estimate of $10.37 billion. During the same quarter last year, the firm posted $1.08 EPS. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. Analysts forecast that Abbott Laboratories will post 4.66 earnings per share for the current year.
Abbott Laboratories Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 1.93%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Read More
- Five stocks we like better than Abbott Laboratories
- With Risk Tolerance, One Size Does Not Fit All
- Is IonQ Leading the Quantum Revolution? Major Deals Fuel Growth
- Earnings Per Share Calculator: How to Calculate EPS
- Why NetApp’s AI-Driven Data Solutions Make It a Top Tech Stock
- ETF Screener: Uses and Step-by-Step Guide
- Cloud Growth and AI: DigitalOcean’s Winning Formula Explained
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.